These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 23642576)

  • 21. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints.
    van Harten AC; Visser PJ; Pijnenburg YA; Teunissen CE; Blankenstein MA; Scheltens P; van der Flier WM
    Alzheimers Dement; 2013 Sep; 9(5):481-7. PubMed ID: 23232269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applied multimodal diagnostics in a case of presenile dementia.
    Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A
    BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.
    Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD
    Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biomarkers in Alzheimer's disease].
    García-Ribas G; López-Sendón Moreno JL; García-Caldentey J
    Rev Neurol; 2014 Apr; 58(7):308-17. PubMed ID: 24677154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.
    Andreasson U; Lautner R; Schott JM; Mattsson N; Hansson O; Herukka SK; Helisalmi S; Ewers M; Hampel H; Wallin A; Minthon L; Hardy J; Blennow K; Zetterberg H
    Mol Psychiatry; 2014 Feb; 19(2):148-9. PubMed ID: 23419830
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
    Mouton-Liger F; Paquet C; Dumurgier J; Lapalus P; Gray F; Laplanche JL; Hugon J;
    Biol Psychiatry; 2012 May; 71(9):829-35. PubMed ID: 22281122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arguments against the biomarker-driven diagnosis of AD.
    Chiu HF; Brodaty H
    Int Psychogeriatr; 2013 Feb; 25(2):177-81. PubMed ID: 23149001
    [No Abstract]   [Full Text] [Related]  

  • 36. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
    Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
    Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
    Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
    Lodeiro M; Ibáñez C; Cifuentes A; Simó C; Cedazo-Mínguez Á
    J Alzheimers Dis; 2014; 41(1):223-32. PubMed ID: 24595197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy.
    Herukka SK; Pennanen C; Soininen H; Pirttilä T
    J Alzheimers Dis; 2008 May; 14(1):51-7. PubMed ID: 18525127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.